Citations

Mayo Clinic

Showing 10 of 108572 citations.

Aggressive Angiomyxoma of the Pelvis: 35-Year Experience
Lara, Francisco J. Cardenas , Perry, William , Kelley, Scott R. , Cardenas Lara, Francisco J, Kelley, Scott R , Perry, William R , Bauzon, Justin S.

Diseases of the Colon & Rectum | December 15, 2023 | Volume: 67 | Issue: 4 | Pages: 514-522

10.1097/dcr.0000000000003152 | PMID 38100620 Get It

BACKGROUND: Aggressive angiomyxoma is a very rare mesenchymal tumor most commonly found in the pelvic and perineal regions. Although many are estrogen and progesterone hormone receptor positive, the pathogenesis is unknown. Due to its rarity, there is a paucity of literature relating to this pathology. This article presents a case series on the management of aggressive angiomyxoma of the pelvis. OBJECTIVE: To present a 35-year experience managing aggressive angiomyxoma of the pelvis. DESIGN: This was a retrospective single-system analysis. SETTINGS: This study was conducted at a quaternary referral academic health care system. PATIENTS: All patients treated for aggressive angiomyxoma of the pelvis. INTERVENTIONS: All patients underwent surgical or medical management of their disease. MAIN OUTCOME MEASURES: The primary outcomes were disease recurrence and mortality. Secondary outcomes included risk factors for recurrence. RESULTS: A total of 32 patients (94% women) were identified with a median follow-up of 65 months. Thirty patients (94%) underwent operative resection and 2 patients were treated solely with medical management. Fifteen achieved an R0 resection (negative microscopic margins) at the index operation, of which 4 (27%) experienced tumor recurrence. There were no mortalities. No risk factors for disease recurrence were identified. LIMITATIONS: Limitations to our study include its nonrandomized retrospective nature, single health care system experience, and small patient sample size. CONCLUSIONS: Aggressive angiomyxoma is a rare, slow-growing tumor with locally invasive features and a high potential for recurrence even after resection with negative margins. Imaging modalities such as CT or MRI should be obtained to aid in diagnosis and surgical planning. Workup should be paired with preoperative biopsy and testing for hormone receptor status, which can increase diagnostic accuracy and guide medical treatment. Close posttreatment surveillance is imperative to detect recurrence. See Video Abstract. ANGIOMIXOMA AGRESIVO DE PELVIS: EXPERIENCIA DE 35 AÑOS ANTECEDENTES: El angiomixoma agresivo es un tumor mesenquimal muy raro que se encuentra más comúnmente en las regiones pélvica y perineal. Aunque muchos son positivos para los receptores hormonales como el estrógeno y la progesterona, la patogénesis es aún desconocida. Debido a su rareza, existe escasa literatura relacionada con esta patología. Este artículo presenta una serie de casos sobre el tratamiento del angiomixoma agresivo de pelvis. OBJETIVO: Presentar una experiencia de 35 años en el manejo del angiomixoma agresivo de pelvis. DISEÑO: Este fue un análisis retrospectivo de sistema único. AJUSTES: Este estudio se llevó a cabo en un sistema de salud académico de referencia de nivel cuaternario. PACIENTES: Todos los pacientes tratados por angiomixoma agresivo de pelvis. INTERVENCIONES: Todos los pacientes se sometieron a tratamiento quirúrgico y/o médico de su enfermedad. PRINCIPALES MEDIDAS DE RESULTADO: Los resultados primarios fueron la recurrencia de la enfermedad y la mortalidad. Los resultados secundarios incluyeron factores de riesgo de recurrencia. RESULTADOS: Se identificaron un total de 32 pacientes (94% mujeres) con una mediana de seguimiento de 65 meses. Treinta (94%) fueron sometidos a resección quirúrgica y dos fueron tratados únicamente con tratamiento médico. Quince lograron una resección R0 (márgenes microscópicos negativos) en la operación inicial, de los cuales cuatro (27%) experimentaron recurrencia tumoral. No hubo mortalidades. No se identificaron factores de riesgo para la recurrencia de la enfermedad. LIMITACIONES: Las limitaciones de nuestro estudio incluyen su naturaleza retrospectiva no aleatoria, la experiencia de un solo sistema de atención médica y el tamaño pequeño de la muestra de pacientes. CONCLUSIONES: El angiomixoma agresivo es un tumor raro, de crecimiento lento, con características localmente invasivas y un alto potencial de recurrencia incluso después de una resección con márgenes negativos. Se deben obtener modalidades de imágenes como CT y/o MRI para la ayuda diagnóstica y la planificación quirúrgica. El estudio debe combinarse con una biopsia preoperatoria y pruebas del estado de los receptores hormonales, que pueden aumentar la precisión del diagnóstico y guiar el tratamiento médico. Es imperativa una estrecha vigilancia posterior al tratamiento para detectar recurrencia. (Traducción—Dr Osvaldo Gauto)
In Response
D’Souza, Ryan S. , Dunn, Lauren K. , D'Souza, Ryan S

Anesthesia & Analgesia | December 15, 2023 | Volume: 138 | Issue: 1 | Pages: e4-e5

10.1213/ane.0000000000006771 | PMID 38100812 Get It

Crossmatch assays in transplantation: Physical or virtual?: A review
Rocha, Yermis , Jaramillo, Andrés , Neumann, Jorge , Hacke, Katrin , Palou, Eduard , Torres, Juan, Jaramillo, Andres , Torres, Juan Manuel

Medicine | December 15, 2023 | Volume: 102 | Issue: 50 | Pages: e36527

10.1097/md.0000000000036527 | PMID 38115324 Get It

The value of the crossmatch test in assessing pretransplant immunological risk is vital for clinical decisions, ranging from the indication of the transplant to the guidance of induction protocols and treatment with immunosuppressants. The crossmatch tests in transplantation can be physical or virtual, each with its advantages and limitations. Currently, the virtual crossmatch stands out for its sensitivity and specificity compared to the physical tests. Additionally, the virtual crossmatch can be performed in less time, allowing for a reduction in cold ischemia time. It shows a good correlation with the results of physical tests and does not negatively impact graft survival. Proper communication between clinicians and the transplant immunology laboratory will lead to a deeper understanding of each patient’s immunological profile, better donor–recipient selection, and improved graft survival.
Dual AApoAIV amyloidosis and ATTR amyloidosis arising in the same patient: a report of three cases
Dalland, Joanna , Dao, Linda N. , Dasari, Surendra , Theis, Jason D. , Chiu, April , Howard, Matthew T., Grogan, Martha , Hagen, Catherine E. , Bois, Melanie C. , Hagen, Catherine, Hagen, Catherine E , Rech, Karen L. , McPhail, Ellen Darcy

Amyloid | December 15, 2023 | Volume: 31 | Issue: 2 | Pages: 153-155

10.1080/13506129.2023.2292949 | PMID 38099717 Get It

Detection of Histoplasma capsulatum and Blastomyces dermatitidis antigens in serum using a single quantitative enzyme immunoassay
Granger, Dane, Streck, Nicholas , Theel, Elitza S. , Streck, Nicholas T

Journal of Clinical Microbiology | December 15, 2023 | Volume: 62 | Issue: 1 | Pages: No page available

10.1128/jcm.01213-23 | PMID 38099670 Get It

ABSTRACT Histoplasma and Blastomyces antigen detection assays are commonly used diagnostic tools. However, a high level of cross-reactivity between these antigens prevents definitive pathogen identification by these assays alone. Retrospective analysis of 3,529 patients with Histoplasma and Blastomyces antigen testing performed on the same serum sample yielded an overall percent agreement of 99.3% (3,506 of 3,529; kappa: 0.859) between the two assays, suggesting that use of a single assay to detect both antigens may be an alternative diagnostic approach. We assessed performance of the Gotham BioTech Blastomyces antigen (GBA) enzyme immunoassay (EIA) (Portland, Maine) for detection of Blastomyces and Histoplasma antigens in serum. Comparison to the MiraVista Diagnostics Blastomyces (MVB) EIA showed 100% positive (24 of 24), negative (57 of 57), and overall (81 of 81) percent agreement. Additionally, 171 sera were used to compare the GBA EIA to the MiraVista Diagnostics Histoplasma (MVH) EIA, which showed 91.3% (63 of 69), 98% (100 of 102), and 95.3% (163 of 171) positive, negative, and overall percent agreement, respectively. Among eight patients with discordant GBA/MVH EIA results, seven had additional fungal testing performed, and results suggested that the MVH and GBA results were inaccurate for two and five samples, respectively. Overall, this study suggests that the GBA EIA has a high level of agreement with both of the commonly used, individual Blastomyces and Histoplasma antigen EIAs. By taking advantage of the high level of cross-reactivity between Blastomyces and Histoplasma antigen EIAs, utilization of a single antigen detection assay for these fungi provides an opportunity to optimize test utilization and decrease patient cost while maintaining a high level of diagnostic accuracy.
Steatotic liver disease, a useful construct in primary care that doesn’t upset the apple cart
Abdelmalek, Manal F. , Rinella, Mary E. , Rinella, Mary , Abdelmalek, Manal

Hepatology | December 15, 2023 | Volume: 79 | Issue: 6 | Pages: 1252-1254

10.1097/hep.0000000000000724 | PMID 38100309 Get It

Frontal Osteomyelitis and Sinusitis Complication After Type III Frontal Bone Cranioplasty for Facial Feminization
Brown, Adam E. , Shrout, Max A., Howard, Brittany E.

Facial Plastic Surgery & Aesthetic Medicine | December 15, 2023 | Volume: 26 | Issue: 1 | Pages: 79-82

10.1089/fpsam.2022.0397 | PMID 38100319 Get It

Background: Forehead contouring can be a component of facial feminization surgery (FFS). Its complications have been rarely reported on and are often described as “hypothetical.” Methods: A case report of complications from forehead contouring resulting in frontal osteomyelitis and sinusitis. Results: A female patient presented with frontal osteomyelitis, sinusitis, and forehead contour deformity after a type III forehead contouring surgery. She had failed prior treatment including oral antibiotics, IV antibiotics, revision sinus surgery, and revision nasal surgery. For definitive treatment, she underwent an anterior table resection, sinus obliteration with bony contouring, and pericranial flap. Conclusions: Forehead contouring represents a recent significant advancement in FFS and gender-affirming therapy. Descriptions of complications and their management are important when novel therapies such as FFS are introduced. This case demonstrates complications from type III forehead contouring including osteomyelitis, frontal sinusitis, and forehead deformity.
Racial, Ethnic, and Geographic Disparities in Immunization Rates Among Patients With Inflammatory Bowel Disease
Beniwal‐Patel, Poonam , Waclawik, Gabrielle, Browning, Keely, Urmat, Aijan, Schell, Trevor , Smith, Ryan C. , Huerta, Antonio, Hipp, Lauren E. , Davé, Sonya , Shah, Neemit , Dillon, Kayla E, Reiter-Schreurs, Katelyn, Russ, Rachel K., Mailig, Miguel, Osman, Fauzia , Weiss, Jennifer , Caldera, Freddy , Caldera, Freddy , Schell, Trevor L , Huerta, Antonio, Dillon, Kayla , Farraye, Francis A. , Hayney, Mary S.

Crohn's & Colitis 360 | December 15, 2023 | Volume: 5 | Issue: 4 | Pages: No page available

10.1093/crocol/otad078 | PMID 38130948 Get It

Abstract Background and Aims Racial and ethnic disparities exist in the treatment of IBD. These disparities exist in adult vaccine uptake among the general population and may extend to patients with IBD. The primary aim of this study was to determine whether racial, ethnic, or geographic disparities existed in influenza vaccine uptake among patients with IBD. Methods We performed a multicenter, retrospective cohort study evaluating adult vaccine uptake among patients with IBD seen at two tertiary referral centers between September 2019 and February 2020. The primary outcome was to determine if racial/ethnic and geographic disparities existed in influenza vaccine uptake for the two prior seasons. Our secondary outcomes were to determine if disparities existed for pneumococcal, zoster, or hepatitis B vaccines. Results Among the 2453 patients who met the inclusion criteria, most identified as non-Hispanic White (89.9%), were on immunosuppressive therapy (74.5%), and received the influenza vaccine in both seasons (56.0%). Older age (prevalence ratio (PR) 0.98; 95% confidence interval (95%CI) 0.98-0.99; P < .001) and non-Hispanic White patients (PR 0.76, 95%CI 0.59–0.98, P < 0.03) were significantly more likely to be immunized. Black patients (PR 1.37; 95%CI 1.18–1.59; P < .001) and those living in underserved geographic areas (PR 1.35; 95%CI 1.17–1.56; P < 0.001) were less likely to be immunized. Racial/ethnic and geographic disparities were identified for pneumococcal, zoster, and hepatitis B vaccine uptake. Conclusions Racial and ethnic vaccination uptake disparities exist among patients with IBD; patients from medically underserved areas are also vulnerable to these disparities Studies identifying patient, provider, and system-level opportunities to address these disparities are needed.